U.S. Markets closed

Is PDL BioPharma, Inc. a Buy?

Keith Speights, The Motley Fool

PDL BioPharma, Inc. (NASDAQ: PDLI) ranks as one of the most intriguing stories in the biopharmaceutical world. Once a dividend king with a patent portfolio that included some of the biggest-selling drugs in the world, such as Avastin and Herceptin, PDL now doesn't pay a dividend at all, and its lucrative patents have expired. Between mid-2014 and the end of 2016, the company lost nearly 80% of its market cap.

But PDL BioPharma appears to be on the rebound now in a big way. Over the past 12 months, the stock is up more than 40%. Is PDL BioPharma now a buy? Here are the arguments for and against the stock. 

Question mark made of stacks of cash

Image source: Getty Images.

The case for PDL BioPharma

Which healthcare stocks would a top artificial-intelligence system buy? That doesn't have to be a hypothetical question. The AI Powered Equity ETF (AIEQ) launched by Equbot is powered by IBM Watson, one of the most famous AI technology platforms around. And the AI system ranks PDL BioPharma as one of its top five healthcare picks.

While the ETF doesn't reveal details behind the AI system's decisions, it's not too hard to see why PDL BioPharma could be attractive. PDL's market cap currently stands near $440 million. The company reported a cash stockpile, including cash, cash equivalents, and short-term investments, of $532 million at the end of 2017. Yes, PDL BioPharma has more cash than the market says the company is worth right now. 

The company also appears to be moving past the devastating impact of the expiration of most of its Queen et al. patent royalties. For the first time in several years, PDL BioPharma grew year-over-year revenue and earnings in 2017. 

One significant growth driver for PDL BioPharma is its majority ownership of Noden Pharma, which markets blood pressure drug Tekturna. The Noden deal, made in 2016, was PDL's first foray into acquiring a commercial-stage asset that could generate income from product sales.

PDL BioPharma has a solid history of finding income-generating opportunities. If the company can make more deals like the Noden transaction, the stock's rebound should continue.

The case against PDL BioPharma

So why shouldn't investors buy PDL BioPharma stock? For one thing, it will be much harder to post more year-over-year revenue and earnings growth in 2018. 

The biggest factor behind PDL's top- and bottom-line success last year was an increase in the fair value estimate for PDL's Depomed (NASDAQ: DEPO) royalty asset. In 2013, PDL acquired rights to receive royalties and milestone payments on type 2 diabetes products licensed by Depomed. These products include Glumetza, Janumet XR, and Invokamet XR. However, this was only a one-time benefit.

It's also important to note that these diabetes products could face challenges. Teva Pharmaceutical launched a generic version of Glumetza in the U.S. during 2017. Merck has encountered headwinds for Janumet because of competition from newer SGLT-2 diabetes drugs, with Johnson & Johnson experiencing a similar story with Invokana and Invokamet. This could mean lower royalties are ahead for PDL BioPharma.

Over 11% of PDL's total revenue still comes from its Queen et al. patents, specifically from the licensing of Tysabri to Biogen. However, Biogen notified PDL in November 2017 that the supplies of Tysabri that had been manufactured prior to patent expiry has been depleted in the U.S. and would soon be used up in other countries as well. That means royalty revenue for PDL will significantly drop this year and will go away after the first quarter of 2019. 

Finding good revenue opportunities is also tougher than it might seem. PDL recently abandoned plans to acquire Neos Therapeutics after the two parties couldn't agree on terms for a deal.

But what about PDL BioPharma's valuation? Although the company does have a cash stockpile larger than its market cap, remember that PDL also has long-term debt totaling more than $200 million. PDL's net cash position is well below its market cap.   

Final verdict

Is PDL BioPharma stock a buy? Despite continuing to face serious challenges, I think buying a small position in the stock could pay off over the long run. The company has moved past the worst damage from expiration of the Queen et al. patents. Its stock is definitely cheap. And although the Neos acquisition didn't pan out, PDL will make more deals in the future.

Having said that, PDL BioPharma certainly isn't my favorite biopharmaceutical stock. There are several other picks that have more solid growth prospects with attractive valuations. But for value investors with a long-term perspective, PDL BioPharma looks like an intriguing bargain buy.

More From The Motley Fool

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool is short shares of IBM. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah

  • Business
    Investopedia

    Market Sell-Off 80% Over, Will Be Reversed by Stock Repurchases: JPMorgan

    Last week, global markets were hit with a widespread shock that weighed on nearly all asset classes, encompassing even the cryptocurrency space, once viewed as a type of "safe haven" bet unrelated to the broader market. In a note to clients on Thursday, JPMorgan equity strategist Dubravko Lakos-Bujas and team forecasted for U.S. equities to make a comeback as fundamentals come back into play, highlighting stock buybacks as a key driver of the nine-year-bull market, as reported by CNBC.

  • Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday
    Business
    Motley Fool

    Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday

    Analyst Pierre Ferragu from financial firm New Street Research set his price target for AMD at $18 per share, arguing that the stock has been priced for a level of success that simply isn't realistic. "AMD's stock price reflects a scenario we don't believe possible," Ferragu wrote. In particular, Ferragu sees larger rival Intel (NASDAQ: INTC) getting its manufacturing act together as we speak.

  • Marijuana investors may lose 90% of their money in Canada, so consider the really big prize elsewhere
    News
    MarketWatch

    Marijuana investors may lose 90% of their money in Canada, so consider the really big prize elsewhere

    Marijuana presents a tremendous opportunity for investors over the next few years. Naïve investors are excited. The reality is that professionals will pick their pockets, and many naïve investors who are excited now will end up losing 90% of their investment.

  • Suddenly Toxic, Saudi Prince Is Shunned by Investors He Courted
    World
    Bloomberg

    Suddenly Toxic, Saudi Prince Is Shunned by Investors He Courted

    Now Crown Prince Mohammed bin Salman could become the biggest risk to his own project. Everything changed when Jamal Khashoggi walked into the Saudi consulate in Istanbul on Oct. 2 and didn’t come out. Prince Mohammed, who’s denied any knowledge of Khashoggi’s fate, still has his defenders -– notably Donald Trump.

  • Tesla slides after Elon Musk announced lower-cost Model 3 (TSLA)
    Business
    Business Insider

    Tesla slides after Elon Musk announced lower-cost Model 3 (TSLA)

    Tesla CEO Elon Musk announced on Twitter on Thursday that a lower-cost Model 3 was immediately available for order on the company's website. The electric car will have a base price of $45,000 and is eligible for federal and state tax rebates. Tesla shares were down more than 3% Friday after — they gained as much as 2.2% earlier in the session.

  • Why Valero Energy, eBay, and New Age Beverages Slumped Today
    Business
    Motley Fool

    Why Valero Energy, eBay, and New Age Beverages Slumped Today

    Some major market benchmarks managed to hang onto their gains, but the Nasdaq Composite, and Russell 2000 indexes posted losses of 0.5% to 1.25%, and the S&P 500 was virtually flat. Valero Energy (NYSE: VLO), eBay (NASDAQ: EBAY), and New Age Beverages (NASDAQ: NBEV) were among the worst performers on the day. Valero Energy dropped 10% after the refinery company announced that it would buy back all outstanding units of its related MLP, Valero Energy Partners (NYSE: VLP).

  • 3 Energy Stocks You Can Buy and Hold for the Next Decade
    Business
    Motley Fool

    3 Energy Stocks You Can Buy and Hold for the Next Decade

    North America needs to build $23 billion of new natural gas-related infrastructure annually through 2035, according to a recent report. Three of the best positioned to capture this growth are Kinder Morgan (NYSE: KMI), Williams Companies (NYSE: WMB), and TransCanada (NYSE: TRP), making them great stocks to buy and hold in the coming decade. Kinder Morgan is already the largest natural gas pipeline company in North America, operating roughly 70,000 miles of pipeline.

  • Looks like when millennials have some money, they get an ...
    AXP
    CNBC Videos

    Looks like when millennials have some money, they get an ...

    CNBC's 'Squawk on the Street' team discusses markets ahead of the market open.

  • Hate Taxes? 37 States Make Social Security Tax Free
    Business
    Motley Fool

    Hate Taxes? 37 States Make Social Security Tax Free

    Over the course of your career, you'll probably have tens of thousands of dollars in Social Security payroll taxes withheld from your paychecks. Workers are confident that by paying those taxes up front, they'll be able to collect Social Security benefits

  • Here are all of the Sears and Kmarts left in the U.S.
    Finance
    Yahoo Finance

    Here are all of the Sears and Kmarts left in the U.S.

    The inevitable has happened to the once-storied Sears. On October 15, Sears filed for Chapter 11 bankruptcy protection after being crippled from years of losses, market share loss to Amazon (AMZN), Macy’s (M) and others, and mounting debt. Sears (SHLD

  • 3 Things Netflix Management Wants Investors to Know
    Business
    Motley Fool

    3 Things Netflix Management Wants Investors to Know

    Netflix (NASDAQ: NFLX) had a monster third quarter. The streaming giant bounced back from its disappointing second quarter (in which it still added 5.45 million paying subscribers) to exceed its Q3 projections by adding 6.15 million new subscribers. The

  • Will Cloud and Improving Margins Dominate Amazon's Earning Report?
    Business
    Motley Fool

    Will Cloud and Improving Margins Dominate Amazon's Earning Report?

    Part of what drove the company to those dizzying heights was the impressive results Amazon has produced so far this year. The company grew revenue an impressive 41% year over year in the first half of 2018, but Amazon Web Services (AWS) is doing even better, up 48% compared to the first six months of last year. All signs point to another strong performance when Amazon reports the financial results of its third quarter after the market close on Thursday, Oct. 25, but let's look at Amazon's most recent results and see what the company will need to do to continue its upward momentum.

  • Should Congress cut entitlement programs to combat rising deficit?
    Politics
    Fox Business Videos

    Should Congress cut entitlement programs to combat rising deficit?

    Maya MacGuineas, Committee for a Responsible Federal Budget, and Wall Street Journal editorial page deputy editor James Freeman discuss America’s deficit problem and how President Trump asked members of his Cabinet to cut their departments’ budgets by 5 percent.

  • 7 Breakout Stocks to Buy That Are “Immune” to Volatility
    Finance
    InvestorPlace

    7 Breakout Stocks to Buy That Are “Immune” to Volatility

    With another disappointing session for the Dow Jones, investors are scrambling to find answers. More than likely, President Donald Trump will face a split government, which may yield increased volatility in Washington. Just recently, Wall Street tumbled when Treasury Secretary Steven Mnuchin decided to withdraw from an investment conference with Saudi Arabia.

  • Don’t cheat yourself with the 4% rule
    Business
    MarketWatch

    Don’t cheat yourself with the 4% rule

    If you’re planning for retirement, you’re probably thinking about how much you’ll need, how long the money will last, and how much you can safely take out each year. You recognize that in retirement there will be a balancing act between spending on current needs while also preserving enough for your later years. Instead, all-too-often, retirees use simplified rules of thumb to determine how much to take out each year.

  • Now is a ‘once-in-a-lifetime’ chance to invest in US pot companies, investor says
    Finance
    Yahoo Finance

    Now is a ‘once-in-a-lifetime’ chance to invest in US pot companies, investor says

    With some Canadian pot stocks posting triple-digit return rates this year, many retail investors have looked north to pour cash into cannabis. U.S. cannabis companies are worth a lot more than their current valuations suggest since federal illegality has put undue pressure on the industry, said David Wenger, a New York attorney and senior editor of the Cannabis Law Digest.

  • Colorado’s Marijuana Market Just Hit This Huge Milestone
    Business
    Motley Fool

    Colorado’s Marijuana Market Just Hit This Huge Milestone

    Marijuana has been legally available in Colorado for recreational use since 2014, and consumers' appetite for marijuana products continues to grow due to the launch of new products, including concentrates and edibles. As a result, Colorado's annual marijuana sales surpassed $1 billion in August -- the earliest it has ever achieved that milestone. There's been some debate over how much money would move from the black market to regulated markets following legalization, but Colorado's experience suggests it's substantial.

  • 1 Top Stock to Buy Amid October’s Turbulent Market
    Business
    Motley Fool

    1 Top Stock to Buy Amid October’s Turbulent Market

    In the past three weeks alone, stocks have tumbled about 5%, which has many investors unnerved. One top option to consider amid the current turbulence is Magellan Midstream Partners (NYSE: MMP), which has lost more than 5% of its value in the past few weeks. Because of that, investors can get an even better starting price on one of the top master limited partnerships (MLPs), potentially setting themselves up to earn market-beating returns in the coming years.

  • America’s Biggest Employer Isn’t Hiring Seasonal Employees This Year. Here’s the Reason Why
    Business
    Money

    America’s Biggest Employer Isn’t Hiring Seasonal Employees This Year. Here’s the Reason Why

    For the third year, Walmart won’t be hiring tens of thousands of seasonal employees to provide extra support during the holidays. Instead, Walmart is forgoing the long-standing practice in favor of giving it’s full- and part-time employees more hours and opportunities to earn extra cash. The idea, Walmart says, is to fulfill the wishes of many of its employees.

  • Why PBF Energy Inc and Other Refining Stocks Are Getting Clobbered Today
    Business
    Motley Fool

    Why PBF Energy Inc and Other Refining Stocks Are Getting Clobbered Today

    Shares of PBF Energy Inc (NYSE: PBF) tumbled as much as 10.9% on Friday, joining a sectorwide sell-off that also saw refiners Valero Energy (NYSE: VLO), Phillips 66 (NYSE: PSX), Marathon Petroleum (NYSE: MPC), and HollyFontier (NYSE: HFC) take it on the chin by sinking more than 5% at one point in the day. A trio of factors seems to be driving these declines.

  • Marijuana stocks to watch: Aurora Cannabis investments may be more valuable than its pot
    News
    MarketWatch

    Marijuana stocks to watch: Aurora Cannabis investments may be more valuable than its pot

    Aurora Cannabis Inc. is a major pot producer, but if its bets on other cannabis companies continue to pay off, it may be able to stop actually growing weed on its own. Aurora (ACBFF)(CA:ACB) said recently its investments were worth more than C$700 million ($540 million) as of Sept. 21, bolstered in part by demand for pot stocks ahead of full legalization of marijuana in Canada on Wednesday. As the entire sector has benefited, so has Aurora’s portfolio, boosting the company’s fiscal fourth-quarter profit to C$79.9 million, after a loss of $20.8 million the year earlier.

  • Why Is Ford Stock Tanking before Its Q3 2018 Earnings Event?
    Finance
    Market Realist

    Why Is Ford Stock Tanking before Its Q3 2018 Earnings Event?

    Why Analysts Are Pessimistic about Ford’s Q3 2018 Earnings  Ford’s Q3 2018 earnings Ford Motor Company (F), the second-largest US automaker by 2017 vehicle sales volume, is set to release its third quarter of 2018 earnings report on October 24. But before

  • Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla
    News
    MarketWatch

    Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla

    The following article is part of a package of stories that MarketWatch is publishing to mark the start of full legalization of cannabis for adult use in Canada on Wednesday. Smith Falls, Ontario–based Canopy Growth Corp. made headlines and drove cannabis stocks to new heights over the summer when it announced that Corona brewer Constellation Brands Inc. was going to invest an additional $4 billion in the company. Billed by both companies as a strategic partnership, the additional $4 billion investment adds to the 9.9% stake that Constellation bought in October of last year and sets the company up to either be bought outright by Constellation — via warrants that could increase its stake to more than 50% — or continue to work with the beverage company to create a range of consumer-focused cannabis products that may one day appear in markets in dozens of countries.

  • Business
    Benzinga

    Morgan Stanley's Recipe For Strong Q4 Guidance From Tesla

    Tesla Inc. (NASDAQ: TSLA) is set to report third-quarter earnings data in early November after a whirlwind of a quarter that included a chain of events that began Aug. 7 with CEO Elon Musk’s “funding secured” tweet and ended with a Securities and Exchange